Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma (NCT00478218), a na phase 2 study. The primary outcome is Number of Participants Who Achieved a Confirmed Response (CR), Very Good Partial Response (VGPR) or Partial Response (PR) During Treatment.

2. Clinical Question

The primary question is about the number of participants meeting a defined response threshold, not a comparison of response rates between randomized groups. A response had to be confirmed on 2 consecutive evaluations during treatment. The registry record describes criteria for complete response (CR), very good partial response (VGPR), and partial response (PR), but does not report the observed number meeting any of these categories or their combined endpoint.

Overall survival, progression-free survival, and duration of response are listed as secondary outcomes. Their definitions, observed results, and statistical analyses are not reported in the registry record. The record therefore identifies the clinical outcomes of interest but does not allow readers to determine the observed response frequency, the duration of response, or how outcomes compared with another treatment or control group.

3. Trial Design

NCT00478218 is listed as a phase II trial sponsored by Mayo Clinic. Its stated aim was to study lenalidomide together with cyclophosphamide and dexamethasone in patients with newly diagnosed multiple myeloma. The registry record gives an enrollment of 53 and a single-group model. Allocation is listed as NA and masking as none; a randomized control group is not described.

The trial started in 2006-07, had a primary completion date of 2008-09, and is listed as completed. These dates describe the registry record, not the timing of each participant’s treatment or follow-up. The primary endpoint timeframe is described as duration of treatment, up to 5 years.

The record lists the three drugs as interventions and names one intervention group, Lenalidomide/Cyclophosphamide/Dexamethasone. Its arm description is blank. In the safety information, the registry separately lists groups titled “LCD (Cyclophosphamide 300 mg/m^2)” and “LCD (Cyclophosphamide 300 mg).” The record does not explain how these safety groups relate to the named intervention group, why the cyclophosphamide dose labels differ, or whether they represent planned cohorts or another grouping.

Because the trial is single group and has no described concurrent control, the primary endpoint is a descriptive response measure rather than a randomized treatment contrast. Allocation procedures beyond the registry entry of NA, treatment schedule, eligibility criteria, and details of follow-up are not reported in the registry record. The record also does not state a sample-size justification or a prespecified statistical analysis plan.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Number of Participants Who Achieved a Confirmed Response (CR), Very Good Partial Response (VGPR) or Partial Response (PR) During Treatment, measured over Duration of Treatment (up to 5 years).

The primary endpoint is the number of participants who achieved a confirmed CR, VGPR, or PR during treatment. Confirmation required the response to be present on 2 consecutive evaluations. The stated timeframe is duration of treatment, up to 5 years. The endpoint combines three response categories, each defined using laboratory or bone-marrow criteria in the registry record.

CR is described as complete disappearance of M-protein from serum and urine on immunofixation, normalization of the free light chain ratio, and <5% plasma cells in bone marrow. VGPR includes a >=90% reduction in serum M-component, urine M-component <100 mg per 24 hours, and <=5% plasma cells in bone marrow. The PR definition includes a >=50% reduction in serum M-component and/or specified urine M-component or free light chain changes. The record’s wording for the PR criteria is not fully clear in places, so those criteria should be read as written rather than reconstructed.

Response categories provide a way to describe antitumor activity using prespecified clinical and laboratory thresholds. Requiring confirmation on consecutive evaluations is intended to distinguish a sustained response from a finding at a single evaluation; that is a general explanation of the purpose of confirmation, not evidence about how often confirmation occurred in this trial. The observed number of participants achieving the endpoint is not reported in the registry record, so the endpoint’s result and precision cannot be assessed from the record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

What does a single-group design estimate?

In a single-group study, outcomes are observed among participants receiving the study intervention, without a concurrent control group described in the registry record. A response count or response proportion, if reported, would describe that study group under its observed conditions. It would not directly estimate how outcomes would differ under another treatment or no treatment. This distinction is general: a descriptive outcome and a comparative treatment effect answer different questions.

The registry record lists the trial model as single group, allocation as NA, and masking as none. These entries do not document random assignment or blinded assessment. They also do not establish that outcome assessments were biased; rather, the record does not provide details with which to evaluate assessment procedures. Further information on assessment masking and allocation is not reported in the registry record.

Why does endpoint definition matter?

A statistical endpoint needs a clear rule for deciding which observations count as events or responses. The primary endpoint combines CR, VGPR, and PR, and requires confirmation on 2 consecutive evaluations. The category criteria include measures of M-protein, the free light chain ratio, and plasma cells in bone marrow. Such thresholds make the outcome more reproducible in principle, but interpretation still depends on consistent measurement, timing, and application of the criteria. Those operational details are not fully described in the registry record.

The endpoint is a count of participants meeting a response definition. In general, a count is easier to interpret when accompanied by the number assessed and an estimate of the response proportion with an uncertainty interval. Those results are not reported in the registry record. It is therefore not possible to infer a response proportion or its precision from the enrollment figure alone.

What would an uncertainty interval contribute?

In general, a confidence interval communicates the statistical uncertainty around an estimated quantity under a specified model and analysis. It does not indicate that every value in the interval is equally likely, and it does not address every source of uncertainty, such as selection or measurement limitations. A narrow interval generally indicates greater statistical precision than a wide interval, while the interval’s interpretation depends on the method and assumptions used. No confidence interval for the primary endpoint is reported in the registry record.

A p-value, in general, assesses how incompatible data are with a specified null model under the assumptions of a statistical test. It is not a measure of clinical importance, the probability that a treatment works, or the probability that the null hypothesis is true. No p-value or inferential test for the primary endpoint is reported in the registry record. In a single-group study, a test would also need a meaningful reference value or comparison defined in advance; such a reference and analysis are not reported.

How should the safety counts be read?

For serious adverse events, the registry lists the number at risk and the number affected in each named safety group. The counts are 13 affected among 34 at risk for “LCD (Cyclophosphamide 300 mg/m^2)” and 2 affected among 19 at risk for “LCD (Cyclophosphamide 300 mg).” These are counts, not estimates of a randomized difference. General comparison of event rates requires clarity about group definitions, event ascertainment, follow-up, and whether groups are comparable. The record does not establish those conditions.

The registry also lists serious adverse-event terms with percentages, including Neutropenia at 14.7%, Thrombosis at 8.8%, Leukopenia at 5.9%, Back pain at 5.9%, Febrile neutropenia at 5.3%, and Death NOS at 5.3%. The denominator and calculation details for these percentages are not reported in the registry record. They should be treated as registry-listed summaries, not as rates recalculated from the group counts.

What assumptions underlie planning illustrations?

General sample-size planning asks how much information would be needed to detect a specified effect under stated design assumptions. The registry record’s planning description refers to a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation, with the target effect expressed as a fraction of an observed effect. It specifies that time-to-event illustrations use total events and other illustrations use participants per arm. These are assumptions for a planning illustration, not a description of this trial’s single-group design or a record of its protocol.

Planning values are not observed power and do not establish the probability that a study result is correct. Their relevance depends on the effect assumption, outcome, design, and analysis. The registry record does not report the trial’s own sample-size justification or enough primary endpoint results to assess an observed effect from the registry entry. No planning value should be interpreted as an observed trial finding.

Over-dispersion is a general concern when count outcomes vary more than a statistical model assumes. If a model underestimates that variability, its uncertainty estimates can be too small and tests can appear more decisive than warranted. The primary endpoint is described as a participant count, but no model for it is reported. The registry record therefore does not indicate whether over-dispersion was assessed or relevant to an analysis.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("LCD (Cyclophosphamide 300 mg/m^2)", "LCD (Cyclophosphamide 300 mg)")
n      <- c(34, 19)
events <- c(28, 16)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  LCD (Cyclophosphamide 300 mg/m^2)  34  28  82.4  65.5  93.2  66.5  91.7  66.4  91.6
ARM  LCD (Cyclophosphamide 300 mg)  19  16  84.2  60.4  96.6  62.4  94.5  62.1  94.3

11. Multiplicity, Missing Data and Analysis Populations

The registry record lists the primary response outcome and three secondary outcomes: overall survival, progression-free survival, and duration of response. It also lists four outcome measures and zero analyses. The record does not report which outcomes were analyzed, how each was analyzed, or whether any additional outcomes were considered. Results for the secondary outcomes are not reported in the registry record.

Multiplicity arises in general when several outcomes, time points, subgroups, or statistical tests are examined. Without an analysis plan, readers cannot determine whether a method was used to control the chance of false-positive findings across multiple tests, or how the primary outcome was distinguished from exploratory analyses. A multiplicity plan is not reported in the registry record. No inference should be made that adjustment was or was not performed outside the information recorded.

Missing-data methods and analysis populations are also not reported in the registry record. The record does not state how participants without an evaluable response, incomplete follow-up, or unavailable measurements were handled. It does not define an intention-to-treat, per-protocol, or other analysis population. The enrollment figure alone does not establish how many participants contributed to a particular endpoint analysis.

These omissions matter because the number analyzed, rules for handling unavailable measurements, and outcome-selection procedures can affect both an estimate and its uncertainty. Without those details or the observed endpoint result, the response outcome cannot be independently checked or interpreted as an estimate for a clearly specified analysis population.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: neutropenia (14.7%), thrombosis (8.8%), leukopenia (5.9%), back pain (5.9%), febrile neutropenia (5.3%).

The registry lists serious adverse-event counts for two safety groups. In “LCD (Cyclophosphamide 300 mg/m^2),” 13 participants were affected among 34 at risk. In “LCD (Cyclophosphamide 300 mg),” 2 were affected among 19 at risk. These are the recorded group counts; the registry does not explain the relationship between the groups or report a randomized comparison between them.

The record also lists serious adverse-event terms and percentages: Neutropenia, 14.7%; Thrombosis, 8.8%; Leukopenia, 5.9%; Back pain, 5.9%; Febrile neutropenia, 5.3%; and Death NOS, 5.3%. The denominator and method used for these percentages are not reported in the registry record. The percentages should not be assumed to use the group counts as denominators.

These figures are descriptive registry entries. They do not, by themselves, establish that an event was caused by a study drug or permit a fair comparison between the differently labelled groups. Follow-up duration by group, event definitions beyond the serious-event listing, and details of ascertainment are not reported in the registry record. The safety counts should therefore be interpreted with those limits in mind.

13. What the Result Does, and Does Not, Mean

The registry record establishes that a phase II study examined lenalidomide, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma, with a confirmed response count as its primary endpoint. It also records secondary outcomes and selected serious adverse-event information. These details identify the clinical question and some of the outcomes the study intended to assess.

The record does not report the observed primary response count or its uncertainty. It therefore cannot establish the frequency of confirmed responses in the study group from the information recorded. It also cannot show whether outcomes differed from those under another treatment, because no concurrent comparator is described. The absence of a reported result is not evidence that the endpoint was or was not met.

In general, a single-group response result, if available, would describe the observed group and would not alone separate treatment effects from other explanations. A controlled comparison can address a different question, but this registry entry does not describe one. Likewise, the listed serious adverse-event counts describe recorded events; they do not establish causation or support an unadjusted causal comparison across the two safety group labels.

The response criteria and timeframe are useful for understanding what the study intended to count, but details of outcome assessment, missing-data handling, analysis populations, and statistical methods are not reported in the registry record. The secondary outcomes are named without results. Accordingly, the record supports a description of the study design and endpoint definitions, but not a conclusion about the magnitude, precision, or comparative meaning of efficacy outcomes.

These limits concern what can be inferred from the registry record. They do not establish that additional results or analyses do not exist elsewhere; such information is simply not reported in the registry record.

14. Why This Trial Matters Statistically

This trial is statistically notable because its primary endpoint is a clearly framed response count in a single-group phase II design. The endpoint combines CR, VGPR, and PR and requires confirmation on 2 consecutive evaluations. That definition focuses the clinical question, while the single-group model sets an important boundary on interpretation: an observed response frequency would describe the treated group rather than a randomized contrast.

The registry record also illustrates the difference between a registered outcome and a reported result. It gives the response criteria and names secondary outcomes, but does not report the primary response count, an uncertainty interval, or statistical analyses. Without those quantities, readers cannot assess the response estimate’s precision or check how outcomes were analyzed. This is a substantive limitation for statistical interpretation, not merely a missing presentation detail.

The safety entries further show why denominators and group definitions matter. The record gives serious-event counts for two differently labelled cyclophosphamide groups, but does not explain their relationship or describe them as randomized comparators. The percentages listed for individual serious-event terms lack a reported denominator. Clear context is needed before counts or percentages can be compared or interpreted as risks.

Finally, the record names overall survival, progression-free survival, and duration of response, but provides no results or analysis details for them. The absence of a reported multiplicity plan, missing-data approach, analysis populations, and sample-size justification also limits assessment of the intended statistical framework. Together, these features make the study question and endpoint definitions identifiable while leaving its outcome evidence and inferential strength unreported in the registry record.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Important design and reporting details are not reported in the registry record. Eligibility criteria, participant characteristics, treatment schedule, dose-modification rules, and follow-up procedures are not described in the trial details presented. The arm description is blank, and the record does not clarify how the two safety groups with different cyclophosphamide dose labels relate to the named intervention group.

The primary endpoint is defined, but the observed response count, number assessed, and uncertainty interval are not reported. The record gives no results for the listed secondary outcomes. Statistical methods, analysis populations, missing-data handling, multiplicity procedures, and the trial’s sample-size justification are also not reported. These gaps prevent assessment of the analysis population, precision, and robustness of any efficacy estimate from this record.

The single-group design lacks a concurrent control described in the registry record, so it cannot provide a randomized comparison. Allocation is listed as NA and masking as none; further information on assignment and outcome assessment is not reported. The serious adverse-event summaries are descriptive, with no reported basis for treating the differently labelled safety groups as comparable. The denominator for the listed serious-event percentages is also not reported.

The registry record describes the study as completed and gives start and primary completion dates, but these entries do not resolve the missing outcome and analysis information. The limitations concern the evidence available in the registry record and should not be taken as claims about unreported documents or analyses.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma — NCT00478218.
• Registry record last updated 2011-08-31; status last verified 2011-08.
• Results first posted 2011-07-27.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

NCT00478218 is a completed phase II, single-group trial sponsored by Mayo Clinic, with an enrollment of 53. It studied lenalidomide, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma. The trial started in 2006-07 and has a primary completion date of 2008-09. Allocation is listed as NA and masking as none.

The primary endpoint is the number of participants with a confirmed CR, VGPR, or PR during treatment, with a timeframe of up to 5 years. Overall survival, progression-free survival, and duration of response are listed as secondary outcomes. The observed primary endpoint result, secondary outcome results, and statistical analyses are not reported in the registry record.

Serious adverse-event counts are listed for two cyclophosphamide-labelled safety groups, along with percentages for selected serious-event terms. The registry record does not explain the relationship between those groups or provide the denominator for the term percentages. Its design and reporting support a description of the study question and registered outcomes, but not an estimate of response or a controlled comparison.